DAIC

DECEMBER 29, 2023

Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF. The company now anticipates U.S. Circulation.

Atrial Fibrillation 115

Atrial Fibrillation Ablation Atrial Flutter Blood Clot 115

DAIC

DECEMBER 14, 2023

Launching the first FDA -approved PFA technology is not just a milestone; the PulseSelect PFA system is setting a new standard in safety for AF ablation with excellent efficacy and efficiency 1. In my clinical experience with the catheter, it was designed for AF ablation procedures.

Atrial Fibrillation 105

Atrial Fibrillation Ablation Technology Heart Failure 105

CardiacWire

DECEMBER 17, 2023

The AFib pulsed field ablation treatment era officially began in the US last week, following the FDA approval of Medtronic’s PulseSelect Pulsed Field Ablation System for the treatment of both paroxysmal and persistent atrial fibrillation. PFA systems use electroporation (short electrical pulses) to achieve pulmonary vein isolation.

AFIB 105

AFIB Ablation Atrial Fibrillation Pulmonary 105

Journal of Cardiovascular Electrophysiology

JANUARY 28, 2024

Abstract Introduction Some previous studies have reported that a first-step ethanol infusion into the vein of Marshall (EIVOM) with touch-up radiofrequency (RF) ablation can facilitate mitral isthmus (MI) block and improves the ablation outcomes in persistent atrial fibrillation (PeAF) patients. 0.78, p  = .006).

Atrial Fibrillation 75

Atrial Fibrillation Ablation Bicuspid/Mitral Tachycardia 75

DAIC

JULY 24, 2024

Volta Medical has announced it has entered into a Joint Development Agreement with GE Healthcare to enhance arrhythmia procedures with artificial intelligence (AI)-driven electrophysiology technologies. Our mission to combat complex heart rhythm diseases relies on optimizing interoperability. The company has obtained U.S.

Atrial Fibrillation 105

Atrial Fibrillation AFIB Ablation Technology 105

Circulation: Arrhythmia and Electrophysiology

JANUARY 29, 2024

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:High-power short-duration ablation has shown impressive efficacy and safety for pulmonary vein isolation (PVI); however, initial efficacy results with very high power short-duration ablation were discouraging. rates between 90W and 50W.

Electrophysiology 76

Electrophysiology Atrial Fibrillation Pulmonary Ablation 76

HeartRhythm

AUGUST 27, 2024

Epicardial Marshall bundle (MB) are frequently utilized in left atrial tachycardias (LATs) post atrial fibrillation (AF) ablation with pulmonary vein isolation and substrate modification.

Atrial Fibrillation 40

Atrial Fibrillation Tachycardia Ablation Electrophysiology 40

Frontiers in Cardiovascular Medicine

FEBRUARY 17, 2025

Backgroundwide antral pulmonary vein isolation (PVI) is effective for treating paroxysmal atrial fibrillation (PAF), although time-demanding. Procedural data and electrophysiology (EP) laboratory times were systematically collected and analyzed.

Atrial Fibrillation 52

Atrial Fibrillation Ablation Laboratory Electrophysiology 52

HeartRhythm

JANUARY 6, 2025

Pulsed field ablation (PFA) is a novel modality shown to be safe and efficient.1 1 PFA is conventionally used for pulmonary vein isolation (PVI), but interest has arisen in delivering linear lesions to the posterior wall2 and mitral isthmus.3 3 The durability of these lesion sets has not been well evaluated.

Electrophysiology 40

Electrophysiology Bicuspid/Mitral Arrhythmia Pulmonary 40

Journal of Cardiovascular Electrophysiology

NOVEMBER 5, 2023

Abstract Introduction Carina breakthrough (CB) at the right pulmonary vein (RPV) can occur after circumferential pulmonary vein isolation (PVI) due to epicardial bridging or transient tissue edema. High-power short-duration (HPSD) ablation may increase the incidence of RPV CB.

Pulmonary 40

Pulmonary Ablation Atrial Fibrillation Article 40

Circulation: Arrhythmia and Electrophysiology

DECEMBER 19, 2024

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. We investigate whether additional linear ablation from the superior vena cava to the right atrial septum and cavotricuspid isthmus ablation improves the rhythm outcome of patients with persistent AF undergoing cryoballoon PVI (Cryo-PVI).METHODS:In

Atrial Fibrillation 40

Atrial Fibrillation Ablation Arrhythmia Pulmonary 40

Circulation: Arrhythmia and Electrophysiology

DECEMBER 16, 2024

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. Patients were randomly assigned to either the PVI+SVC ablation group or the PVI-only group. CONCLUSIONS:The addition of SVC ablation to PVI did not enhance freedom from atrial tachyarrhythmia at 12 months, and it led to increased complications. versus 72%;P=0.41).

Ablation 40

Ablation Atrial Fibrillation Electrophysiology Pulmonary 40

Journal of Cardiovascular Electrophysiology

MARCH 3, 2024

Abstract Introduction Through systematic scientific rigor, the CLOSE guided workflow was developed and has been shown to improve pulmonary vein isolation durability. However, this technique was developed at a time when using power-controlled ablation catheters with conventional power ranges was the norm.

Ablation 40

Ablation Pulmonary Technology Outcomes 40

HeartRhythm

APRIL 30, 2024

Pulsed-field ablation (PFA) is becoming increasingly relevant in the field of electrophysiology. Besides single-shot PFA devices for pulmonary vein isolation (PVI), point-by-point PFA is also gaining importance due to many possible applications. Data on the use is sparse, especially for atrial tachycardia (AT).

Tachycardia 40

Tachycardia Ablation Electrophysiology Technology 40

Circulation: Arrhythmia and Electrophysiology

NOVEMBER 23, 2023

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. Background:Pulsed field ablation (PFA) has emerged as an alternative to radiofrequency ablation. A contact force–sensing catheter was used to focally deliver PFA/radiofrequency at the pulmonary veins and other predefined sites in the atria.

Ablation 40

Ablation Pulmonary Atrial Fibrillation Electrophysiology 40

Journal of Cardiovascular Electrophysiology

DECEMBER 7, 2023

Abstract Background The newly introduced nonthermal pulsed field ablation (PFA) is a promising technology to achieve fast pulmonary vein isolation (PVI) with high acute success rates and good safety features. Data comparing PFA to VHPSD-PVI is lacking. Two tamponades occurred in the PFA while in VHPSD two pts suffered groin bleedings.

Ablation 40

Ablation Pulmonary Arrhythmia Atrial Fibrillation 40

DAIC

DECEMBER 26, 2023

a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, announced the completion of the first five procedures in its first-in-human feasibility study with its novel CellFX nsPFA cardiac catheter. “We

Ablation 59

Ablation Atrial Fibrillation Technology Cardiothoracic 59

Journal of Cardiovascular Electrophysiology

DECEMBER 7, 2023

After 12 months of follow-up, there was an 81% freedom of AF in general, which was significantly higher in patients treated with robotic magnetic navigation-guided radiofrequency ablation (RMN-RF). Abstract Introduction Pulmonary vein isolation (PVI) is a pivotal part of ablative therapy for atrial fibrillation (AF).

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary Article 40

Circulation: Arrhythmia and Electrophysiology

NOVEMBER 29, 2024

Circulation: Arrhythmia and Electrophysiology, Volume 17, Issue 12 , Page e013208, December 1, 2024. BACKGROUND:The pentaspline pulsed field ablation catheter achieves pulmonary vein isolation using 8 stacked, pose-specific applications with rotation. versus 6.12.0 mm;P=0.02).

Ablation 40

Ablation Pulmonary Electrophysiology Arrhythmia 40

Journal of Cardiovascular Electrophysiology

MARCH 27, 2025

ABSTRACT Background Ultra-low temperature cryoablation (ULTC) is a technique designed to rapidly cool cardiac tissue to extremely low temperatures, enabling the creation of ablation lesions for the treatment of atrial fibrillation (AF). Arrhythmia outcomes after repeat ablation were evaluated.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Arrhythmia Bicuspid/Mitral 40

Journal of Cardiovascular Electrophysiology

DECEMBER 7, 2023

Abstract Introduction Although first-pass isolation (FPI) of the pulmonary vein (PV) has been suggested as a marker for PV isolation (PVI) durability, it has not been confirmed. Non-PV atrial fibrillation (AF) triggers were the main target in patients without PV reconnection in the second ablation procedure, but the outcome was unclear.

Atrial Fibrillation 40

Atrial Fibrillation Pulmonary Ablation Outcomes 40

Journal of Cardiovascular Electrophysiology

JANUARY 11, 2024

In this study, AEPVR (acute epicardial pulmonary vein reconnection) was differentiated in characteristics from endocardial conduction gap in acute PVR (left). We aimed to investigate the prevalence, locations, electrogram characteristics, and ablation parameters related to acute epicardial pulmonary vein reconnection (AEPVR).

Pulmonary 40

Pulmonary Ablation Electrophysiology Article 40

Circulation: Arrhythmia and Electrophysiology

NOVEMBER 3, 2023

Circulation: Arrhythmia and Electrophysiology, Volume 16, Issue 11 , Page e012043, November 1, 2023. BACKGROUND:In patients with persistent atrial fibrillation (PersAF), catheter ablation aiming for pulmonary vein isolation (PVI) is associated with moderate clinical effectiveness.

Atrial Fibrillation 40

Atrial Fibrillation Pulmonary Quality of Life Ablation 40

Journal of Cardiovascular Electrophysiology

DECEMBER 7, 2023

We present the long-term outcome of catheter ablation (CA) and electrophysiological characteristics in HIV+ AF patients. During first procedure, all received isolation of pulmonary vein (PV) + posterior wall and superior vena cava. Among patients that underwent redo ablation non-PV triggers were higher in HIV group [93.5%

Atrial Fibrillation 40

Atrial Fibrillation Ablation Outcomes Arrhythmia 40

Journal of Cardiovascular Electrophysiology

OCTOBER 30, 2024

Abstract Introduction The impact of combining ablation index (AI)-guided and very high-power short-duration (vHPSD) ablation on procedural factors at the posterior wall near the esophagus is unclear. Methods Atrial fibrillation patients who underwent initial ablation using three-dimensional mapping were enrolled.

Ablation 40

Ablation Atrial Fibrillation Pulmonary Article 40

Journal of Cardiovascular Electrophysiology

FEBRUARY 8, 2024

Abstract Introduction Pulsed field ablation (PFA) has emerged as an innovative technique for pulmonary vein isolation (PVI). Typically, a transeptal puncture (TSP) with a standard sheath precedes a switch to the larger diameter sheath in the left atrium.

Pulmonary 40

Pulmonary Ablation Atrial Fibrillation Innovation 40

Journal of Cardiovascular Electrophysiology

DECEMBER 17, 2023

This study investigated myocardial injury and inflammation following pulmonary vein isolation using (1) Standard radiofrequency ablation, (2) very high-power short-duration (vHPSD)-70W, (3) vHPSD-90W, and (4) pulsed-field ablation (PFA). Results Baseline characteristics were well-balanced between groups (age 63.1 ± 10.3

Ablation 40

Ablation Atrial Fibrillation Technology Pulmonary 40

Circulation: Arrhythmia and Electrophysiology

DECEMBER 19, 2024

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:Pulsed field ablation (PFA) is a promising treatment for atrial fibrillation. paroxysmal, and 58.5% deep sedation) were treated. One-year freedom from atrial arrhythmia was 80.2% (95% CI, 69.7%87.4%)

Atrial Fibrillation 40

Atrial Fibrillation Ablation Arrhythmia Outcomes 40

Journal of Cardiovascular Electrophysiology

NOVEMBER 21, 2023

In this large substudy of the AWARE Trial, a high-power short-duration (HPSD) radiofrequency ablation strategy was found to be similarly effective as a low-power long-duration strategy with no difference in time to first recurrence of any AF lasting ≥30 s. The primary outcome was not statistically significant at 30.1% versus 22.2%

Ablation 40

Ablation Pulmonary Atrial Fibrillation Arrhythmia 40

Journal of Cardiovascular Electrophysiology

FEBRUARY 20, 2025

ABSTRACT Introduction The extensive use of pulsed field ablation (PFA) in clinical settings has unveiled new evidence suggesting potential involvement in red blood cell structural impairment resulting in hemolysis and potential acute kidney injury (AKI).

Biomarkers 40

Biomarkers Pulmonary Technology Ablation 40

Journal of Cardiovascular Electrophysiology

JANUARY 28, 2024

Abstract Introduction During atrial fibrillation ablation (AFA), achievement of first pass isolation (FPI) reflects effective lesion formation and predicts long-term freedom from arrhythmia recurrence. We aim to determine the clinical and procedural predictors of pulmonary vein FPI.

Ablation 40

Ablation Pulmonary BMI Atrial Fibrillation 40

Journal of Cardiovascular Electrophysiology

NOVEMBER 11, 2024

This study of 16 patients with persistent left superior vena cava (PLSVC) undergoing atrial fibrillation ablation shows a 66.7% identification rate of PLSVC-related triggers and an 85% success rate in acute isolation or targeted ablation. However, a 46.7% The primary endpoints were procedural safety and AF recurrence postablation.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Outcomes Pulmonary 40

Journal of Cardiovascular Electrophysiology

DECEMBER 10, 2024

Pulsed field ablation (PFA) may overcome the disadvantages of thermal energy and improve both ablation efficacy and safety. Coronary vasospasm occurred (and quickly resolved after injection of nitroglycerin) in one patient during additional ablation of a focal atrial tachycardia at the coronary sinus ostium.

Arrhythmia 40

Arrhythmia Ablation Pulmonary Tachycardia 40

Journal of Cardiovascular Electrophysiology

DECEMBER 7, 2023

FAAM ablation successfully decreased the recurrence rate of atrial tachyarrhythmia compared with conventional non-PV foci ablation. Abstract Introduction Treatment of recurrent atrial fibrillation (AF) is sometimes challenging due to non-pulmonary vein (PV) foci. The RHYTHMIA system was used to perform all the procedures.

Ablation 40

Ablation Atrial Fibrillation Atrial Flutter Tachycardia 40

Journal of Cardiovascular Electrophysiology

DECEMBER 7, 2023

Abstract Introduction Cryoballoon ablation (CBA) of the left atrial (LA) roof in addition to a pulmonary vein isolation has been expected to improve the clinical outcomes post-atrial fibrillation (AF) ablation. Results Complete LA roof line conduction block was obtained in 767 patients (92.0%) solely by CBA (Group A).

Ablation 40

Ablation Pulmonary Atrial Fibrillation Arrhythmia 40

Journal of Cardiovascular Electrophysiology

DECEMBER 3, 2023

Methods and Results This case report discusses a 65-year-old man who had previously undergone pulmonary vein isolation (PVI) and cavo-tricuspid isthmus ablation for atrial fibrillation before ASD closure, respectively. He developed atrial tachycardia (AT) and underwent catheter ablation.

Bicuspid/Mitral 40

Bicuspid/Mitral Ablation Aortic Atrial Fibrillation 40

Journal of Cardiovascular Electrophysiology

NOVEMBER 20, 2024

ABSTRACT Introduction Pulmonary vein (PV) restenosis develops with reported incidence rates of up to 50%. Method and Results A 54-year-old man with long history of atrial fibrillations developed PVS secondary to multiple radiofrequency ablation procedures. Balloon angioplasty seems to be the widely preferred treatment of choice.

Stents 40

Stents Stent Pulmonary Angioplasty 40